Braskem has not exited its crisis — but the world may be deteriorating fast enough to help it. After months in which markets flirted with restructuring scenarios, including judicial or out-of-court processes, the Brazilian petrochemical group is, at last, showing signs of breathing.
The trigger is external — and far from benign. The conflict between the U.S., Israel and Iran has not only lifted oil prices and their derivatives, but has also begun to reshape the global supply structure. What started as a price shock has quickly turned into a shortage of physical feedstock. In Asia, producers are cutting output, running at minimum rates and already warning of shutdowns. Japan and South Korea have only weeks of inventory. In some cases, the issue is no longer price — but availability.
The effect, however, is uneven. In the United States, the same shock has created opportunity. Producers such as Dow and LyondellBasell — which rely on natural gas rather than naphtha — have moved from a depressed cycle to an almost instantaneous expansion in margins. Prices are rising at unusual speed, plants are running near full capacity and shares have surged. With the Middle East partially sidelined, the Gulf Coast has re-emerged as the center of global arbitrage. U.S. producers are redirecting volumes toward Europe and Asia, where margins are higher.
It is within this shifting landscape that Braskem finds some relief. As a naphtha-based producer integrated with Petrobras, it lacks the structural advantage of its U.S. peers. Still, in a tighter market, even weaker players can rebuild pricing — particularly in their domestic markets. But this is not exactly pricing power. Recent increases largely reflect cost pass-through in a market without a clear reference — with constrained supply, rationed volumes and limited visibility. Local measures provide some support, but remain secondary: extended antidumping protections, tariffs on imports and targeted policy backing. The impulse is external — and therefore unstable. What may look like a turning cycle is, instead, a distortion. At the start of the decade, markets were already bracing for margin compression — until the pandemic produced an artificial peak in profitability. In 2021, Braskem posted a record EBITDA of $5.2 billion — a figure that said more about global scarcity than about the company itself. For 2026, market estimates point to roughly $700 million.
The risk is to mistake relief for resolution. The same scarcity that supports margins also erodes demand, accelerates capacity closures and reshapes the global industry. If the U.S. emerges as a temporary winner, the rest of the world — including Braskem — operates closer to survival than advantage. Roughly R$50 billion in debt does not disappear overnight. The new environment does not fix the company — but it may change the price at which it is sold. For Braskem, this is not exactly strategy. It is, in part, luck.